GlaxoSmithKline (GSK) aims to have its respiratory syncytial virus (RSV) vaccine reviewed later this year; Northwell Health and Kaiser Permanente among CEOs supporting gun legislation; Infants whose mothers had COVID-19 during their pregnancy had double the risk of delayed speech or motor skills.
GlaxoSmithKline (GSK) hopes to have their vaccine for respiratory syncytial virus (RSV) reviewed later this year after early data showed that the vaccine was effective in older adults, according to Reuters. RSV has been identified as a leading cause of pneumonia in toddlers and older adults but the complexity of the virus hindered further research into a vaccine for many years. GSK is one of several companies looking into a vaccine; Pfizer, Johnson & Johnson, Sanofi, and Moderna have been testing therapies or vaccines for RSV as well. GSK’s vaccine for RSV is the first to have demonstrated statistically significant efficacy in adults aged 60 years and older, according to the company.
CEOs from Northwell Health, Kaiser Permanente, CentraState Healthcare System, and Headspace Health are among more than 200 companies asking the Senate to take action on gun legislation after the most recent spate of mass shootings. The letter called on the Senate to take action as “the gun violence epidemic represents a public health crisis that continues to devastate communities.”
Infants whose mothers had COVID-19 during their pregnancy had nearly twice the risk of being diagnosed with delayed speech or motor skills by their first birthday, according to a study in JAMA Network Open. The overall risk of developmental delays was low but had risen to 6% in infants who were exposed to COVID-19 in the womb compared with unexposed infants whose risk was about 3%. These lags were in areas including rolling over, reaching for objects, and babbling. The study did not assess the impact of vaccination because the study took place between March and September of 2020, before vaccinations became widely available.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Untangling Medical Debt From Credit Scores: Effects So Far and Next Steps
November 29th 2023After recent policy changes removing most medical debts from credit reports, Americans are seeing their credit scores increase, but experts warn of the need to monitor billing and collection practices for unintended consequences.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen